Key result
Treatment with 5 mg/day ramipril for 4 weeks significantly increased plasma adiponectin levels and decreased proteinuria in type-2 diabetic patients (p<0.001).
Why the study?
Does ramipril increase plasma adiponectin levels and reduce proteinuria in type-2 diabetic patients with proteinuria?
Observational (n=72)
Does ramipril increase plasma adiponectin levels and reduce proteinuria in type-2 diabetic patients with proteinuria?
p-value: p=<0.001
Ramipril treatment for 4 weeks significantly increases plasma adiponectin levels and reduces proteinuria and insulin resistance in type-2 diabetic patients with proteinuria.
Short-term ramipril was associated with higher adiponectin and reduced proteinuria; leaves open whether these changes improve renal outcomes in type 2 diabetes.
BACKGROUND/AIMS: Adiponectin seems to be an important modulator for metabolic and vascular diseases. A case study was designed to measure plasma adiponectin levels and to investigate the effects of angiotensin-converting enzyme inhibitors on adiponectin levels in type-2 diabetic patients with proteinuria. METHODS: Forty-nine patients (28 males, 21 females) and 23 healthy volunteers (13 males, 10 females) were included in the case study. Patients with proteinuria were treated with 5 mg/day ramipril (n = 21) for 4 weeks. RESULTS: Adiponectin levels of patients were significantly lower than those of healthy volunteers (p < 0.001). There were significant negative correlations between adiponectin concentrations and insulin levels as well as the homeostasis model assessment (HOMA) index in the patient group (r = -0.655, p < 0.001; r = -0.469, p = 0.001, respectively). There was also a significant negative correlation between plasma adiponectin concentrations and the degree of proteinuria (r = -0.912, p < 0.001). Plasma adiponectin levels in patients with proteinuria (n = 21; 4.81 +/- 3.17 microg/ml) were significantly lower than those without proteinuria (n = 28; 10.25 +/- 2.03 microg/ml; p < 0.001). After the treatment period, adiponectin levels significantly increased (p < 0.001) and proteinuria, plasma insulin, and HOMA indexes significantly decreased in the treatment group (p < 0.001, p < 0.001, p = 0.002, respectively). CONCLUSIONS: The results suggest that adiponectin is inversely correlated with proteinuria and treatment with ramipril both corrects proteinuria and increases the low adiponectin levels in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Yenicesu et al. (2005) conducted an observational in Type-2 diabetes with proteinuria (n=72). Ramipril vs. Baseline (pre-treatment) was evaluated on Plasma adiponectin levels (p=<0.001). Treatment with 5 mg/day ramipril for 4 weeks significantly increased plasma adiponectin levels and decreased proteinuria in type-2 diabetic patients (p<0.001).